- Home
- FEBO vs BIAF Comparison
FEBO vs BIAF Comparison
Compare FEBO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | BIAF |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.8M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FEBO | BIAF |
|---|---|---|
| Price | $1.33 | $1.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 147.2K | 78.0K |
| Earning Date | 12-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,110,653.00 | $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $0.61 | $1.18 |
| 52 Week High | $2.31 | $46.53 |
Technical Indicators
Market Signals| Indicator | FEBO | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 82.81 | 34.06 |
| Support Level | $0.84 | $1.18 |
| Resistance Level | $1.39 | $1.74 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 91.14 | 11.81 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.